Tauriga Sciences, Inc’.s E-Commerce Fulfillment Center Confirms Arrival of Black Currant Flavor Tauri-Gum Inventory

Black Currant Flavor Tauri-Gum™ is Cannabigerol Infused -
Each Piece of Chewing Gum Contains 15mg CBG

NEW YORK, NY – (NewMediaWire) – August 6, 2020 – Tauriga Sciences, Inc.
(OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating,
diversified life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon,
Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology
initiatives, today announced the arrival of Black Currant flavor Cannabigerol
(“CBG”) infused Tauri-Gum™ inventory – at its E-Commerce fulfillment
center.  This product is the Company’s second CBG version of Tauri-Gum™
and is now available on the Company’s E-Commerce website (  Each piece of Black Currant chewing gum
contains 15mg CBG isolate – MSRP: $21.99 per Blister Pack.

Link to Black Currant CBG Tauri-Gum™ – E-Commerce Store:

Initial Production Run: 
Approximately 8,600 Blister Packs (860 Retail Boxes)

The Company has been experiencing strong levels of interest
in its Black Currant flavor Tauri-Gum™ product, from a broad array of potential
customers and retailers.  The product is Kosher Certified, Vegan
Formulated, Lab Tested, NON-GMO, Allergen Free, Gluten Free, NO THC, and 100%
Made in the USA  


Tauriga Sciences, Inc. (TAUG) is a revenue generating,
diversified life sciences company, engaged in several major business activities
and initiatives.  The company manufactures and distributes several
proprietary retail products and product lines, mainly focused on the
Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™,
consists of a proprietary supplement chewing gum that is both Kosher certified
and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange,
Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon).  The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a fast-growing
E-Commerce business segment (E-Commerce website:
Please visit our corporate website, for additional information, as well as
inquiries, at

Complementary to the Company’s retail business, are its two
ongoing biotechnology initiatives.  The first one relates to the
development of a Pharmaceutical grade version of Tauri-Gum™, for nausea
regulation (specifically designed to help patients that are subjected to
ongoing chemotherapy treatment).  On March 18, 2020, the Company announced
that it filed a provisional U.S. patent application covering its pharmaceutical
grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is
TREATMENT”.  The second one relates to a collaboration agreement with
Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed,
Novel Coronavirus (COVID-19) test with superior sensitivity and

The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain.  In addition, the Company operates a
full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking
statements” as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning future events.
These forward-looking statements are often indicated by using words such as
“may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or
plans, and may include statements regarding corporate objectives as well as the
attainment of certain corporate goals and milestones. Forward-looking statements
are based on present circumstances and on management’s present beliefs with
respect to events that have not occurred, that may not occur, or that may occur
with different consequences or timing than those now assumed or anticipated.
Actual results may differ materially from those expressed in  forward looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of general economic
and business conditions, the ability to successfully develop and market
products, consumer and business consumption habits, the ability to consummate
successful acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no control. Many of
these risks and uncertainties are discussed in greater detail in the “Risk
Factors” section of Tauriga’s Form 10-K and other filings made from time to
time with the Securities and Exchange Commission. Such forward-looking
statements are made only as of the date of this release, and Tauriga assumes no
obligation to update forward-looking statements to reflect subsequent events or
circumstances. You should not place undue reliance on these forward-looking



Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, NY  10022

Chief Executive Officer

Mr. Seth M. Shaw


cell # (917) 796 9926




E-Commerce Website:

Source link

Show More

Related Articles

Back to top button

Get SmallCapDaily's News, Research, Trade Alerts & MORE, all 100% FREE!

Enter your email address to get started. All 100% Free.

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact